PTN Surges On Trial Data, PFE Dumps Cholesterol Drug, Watch Out For PRTA

Shares of Palatin Technologies Inc. (PTN) were up over 57% in extended trading on Tuesday, following positive results from its two phase III trials of Bremelanotide in premenopausal women with hypoactive sexual desire disorder.

from RTT - Biotech http://ift.tt/2fd2UPv
via IFTTT